> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# SS Innovations Sells $21.0 Million Secured Convertible Note For $20 Million, Pledging Its IP
- URL: https://www.bullished.co/ss-innovations-sells-21-0-million-secured-convertible-note-for-20-million-pledging-its-ip-30ff1731/
- Published: 2026-10-13T10:22:47.000Z
- Updated: 2026-10-28T22:33:10.000Z
- Description: The surgical robotics company's 8-K shows an 8.75% note maturing in 36 months, with 8 million shares reserved for conversions.
- Author: Matteo Parrino
- Tags: SEC Filings, SSII, Industry: Healthcare

[SS Innovations International](https://www.bullished.co/tag/ssii/) sold a secured convertible note with [$21,025,000 in principal](https://www.sec.gov/Archives/edgar/data/0001676163/000121390026108624/ea0308062-8k%5Fssinnova.htm?ref=bullished.co) for $20,000,000, according to an [8-K](https://www.bullished.co/learn/8-k-items-explained/) filed Tuesday. The deal closed Friday, and the lender gets a claim on the company's intellectual property and the assets of most of its subsidiaries.

## What the 8-K says

The extra $1,025,000 in principal is $1,000,000 of original issue discount plus $25,000 of the investor's transaction expenses. The note carries 8.75% annual interest, compounded daily, and matures 36 months after closing.

The filing calls the buyer only an institutional investor. The note's [exhibit](https://www.sec.gov/Archives/edgar/data/0001676163/000121390026108624/ea030806201ex4-1.htm?ref=bullished.co) names the lender as Growth Capital Partners, LLC, signed by its president, Scott Brown.

Collateral is the company's intellectual property, held by its Delaware subsidiary SSI IP Holdings, plus the assets of the company and that subsidiary, including equity in other subsidiaries. The Indian operating subsidiary, Sudhir Srivastava Innovations Pvt. Ltd., is excluded, and its assets and stock are not pledged. The other subsidiaries guarantee the note.

## How conversion works

The investor can convert the balance into common stock at 95% of the Market Price, defined as the lower of the prior day's volume-weighted average price and the five-day average of that price. That right applies only on days the shares trade at least 10% above the Market Price.

Daily conversions are capped at the greater of $50,000 or 10% of that day's dollar trading volume. The investor's stake is capped at 4.99% of outstanding shares, which it can raise to 9.99% on 61 days' notice.

From the 12-month anniversary, the investor can also redeem the note monthly, up to the balance at that point divided by 24\. The company can pay in cash or shares. It may prepay on five trading days' notice, with make-whole interest on amounts paid or converted.

The company set aside 8,000,000 shares for conversions and agreed to raise that reserve in 100,000-share increments as required. Shares issued to the investor cannot exceed the Nasdaq issuance cap unless shareholders approve more.

## What it changes

The company now owes a debt backed by its core intellectual property. The note's terms include trigger events, such as missed payments or a non-management-backed proxy filing, that let the lender add to the balance. Defaults can lead to 18% interest and acceleration.

The company's chief executive, Sudhir Srivastava, signed the filing as chairman and interim chief financial officer. Per a [Yahoo Finance commentary](https://finance.yahoo.com/markets/stocks/articles/2-international-microcaps-watchlist-083600389.html?.tsrc=rss&ref=bullished.co) by Mark Zinski, the company reported record second-quarter sales of $13.9 million and a $2.7 million net loss. The piece says it expects an FDA response on its Mantra system's 510(k) application in the first quarter of 2027.

The next things to track are whether the stock trades 10% above the Market Price, which opens conversions, and whether the company seeks shareholder approval to go past the Nasdaq cap.

Learn

- [Item 1.01: entry into a material agreement →](https://www.bullished.co/learn/8-k-items-explained/#item-101-entry-into-a-material-agreement)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — SS Innovations International, Inc. (SSII)](https://www.sec.gov/Archives/edgar/data/0001676163/000121390026108624/ea0308062-8k%5Fssinnova.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit ea030806201ex4-1.htm — SS Innovations International, Inc. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001676163/000121390026108624/ea030806201ex4-1.htm?ref=bullished.co) — SEC EDGAR
- [2 International Microcaps for Your Watchlist](https://finance.yahoo.com/markets/stocks/articles/2-international-microcaps-watchlist-083600389.html?.tsrc=rss&ref=bullished.co) — Yahoo Finance

### More on SS Innovations International

- [SS Innovations CEO Repairs A Patient's Heart Defect From Barcelona, 7,500 Miles Away](https://www.bullished.co/ss-innovations-ceo-repairs-a-patients-heart-defect-from-barcelona-7-500-miles-away-581b79df/)
- [SS Innovations Sends FDA New Study Data On SSi Mantra Robot, Expects Review Done In First Quarter Of 2027](https://www.bullished.co/ss-innovations-sends-fda-new-study-data-on-ssi-mantra-robot-expects-review-done-in-first-39012472/)
- [SS Innovations Targets Europe's CE Mark In Fourth Quarter, FDA Clearance In Early 2027](https://www.bullished.co/ss-innovations-targets-europes-ce-mark-in-fourth-quarter-fda-clearance-in-early-2027-b0fa1d88/)

[All SS Innovations International (SSII) coverage →](https://www.bullished.co/tag/ssii/)